Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke

R.D. Spescha1,2, J. Klohs3, A. Semerano4, G. Giacalone4, R.S. Derungs5, M.F. Reiner1,2, D. Rodriguez Gutierrez1, N. Mendez-Carmona1, M. Glanzmann1,2, G. Savarese1,2, N. Kränkel1,2,6, A. Akhmedov1,2, S. Keller1,2, P. Mochalra1,2, M.R. Kaufmann2,7, R.H. Wenger2,7, J. Vogel8, L. Kolic5, R.M. Nitsch5, J.H. Beer9, L. Peruzzotti-Jametti4, M. Sessa4, T.F. Lüscher1,2,10, and G.G. Camici1,2*

1Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, Schlieren CH-8952, Switzerland; 2Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland; 3Institute for Biomedical Engineering, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland; 4Department of Neurology, San Raffaele Scientific Institute, Milan, Italy; 5Division of Psychiatry Research, University of Zurich, Schlieren, Switzerland; 6Department of Cardiology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; 7Institute of Physiology, University of Zurich, Zurich, Switzerland; 8Institute of Veterinary Physiology, University of Zurich, Zurich, Switzerland; and 9Department of Internal Medicine, Cantonal Hospital of Baden, Baden, Switzerland; and 10Cardiology, University Heart Center, University Hospital, Zurich, Switzerland

Received 16 February 2015; revised 31 March 2015; accepted 6 April 2015; online publish-ahead-of-print 22 April 2015

See page 1573 for the editorial comment on this article (doi:10.1093/eurheartj/ehv175)

**Aim**

Constitutive genetic deletion of the adaptor protein p66Shc was shown to protect from ischaemia/reperfusion injury. Here, we aimed at understanding the molecular mechanisms underlying this effect in stroke and studied p66Shc gene regulation in human ischaemic stroke.

**Methods and results**

Ischaemia/reperfusion brain injury was induced by performing a transient middle cerebral artery occlusion surgery on wild-type mice. After the ischaemic episode and upon reperfusion, small interfering RNA targeting p66Shc was injected intravenously. We observed that post-ischaemic p66Shc knockdown preserved blood–brain barrier integrity that resulted in improved stroke outcome, as identified by smaller lesion volumes, decreased neurological deficits, and increased survival. Experiments on primary human brain microvascular endothelial cells demonstrated that silencing of the adaptor protein p66Shc preserves Claudin-5 protein levels during hypoxia/reoxygenation by reducing nicotinamide adenine dinucleotide phosphate oxidase activity and reactive oxygen species production. Further, we found that in peripheral blood monocytes of acute ischaemic stroke patients p66Shc gene expression is transiently increased and that this increase correlates with short-term neurological outcome.

**Conclusion**


**Keywords**

Stroke • Ischaemia • Reperfusion • Free radicals • Endothelium

**Translational perspective**

In light of the limited repertoire of therapeutical options available for the treatment of ischaemic stroke, the identification of novel potential targets is vital; in this respect, the present study demonstrates that the adaptor protein p66Shc holds this potential as an adjunct therapy to thrombolysis. Post-ischaemic silencing of p66Shc protein yielded beneficial effects in a mouse model of I/R brain injury underlying an interesting...
translational perspective for this target protein. Further, in proof-of-principle clinical experiments using PBMs, we demonstrate that p66Shc gene expression is transiently increased and that its levels correlate to short-term outcome in ischaemic stroke patients. Although these latter experiments are not directly relevant to the experiments performed in mice and in human endothelial cells, they provide novel important information about p66Shc regulation in stroke patients and set the basis for further investigations aimed at assessing the potential for p66Shc to become a novel therapeutic target as an adjunct of thrombolysis for the management of acute ischaemic stroke.

Introduction

Stroke is associated with major disabilities and mortality.1 Although over the last decades several novel experimental neuroprotective strategies have been developed,2 their translation into clinical practice has proven difficult.3,4 Thus, the search for novel therapeutic targets for ischaemic stroke as an adjunct to thrombolysis remains an unmet clinical need.

Although ischaemic stroke is amenable to thrombolysis in patients presenting early after symptom onset,5 vascular leakage and the ensuing oedema formation during reperfusion contributes importantly to neurological deficits.6 Cerebral microvascular endothelial cells are a main component of the blood–brain barrier (BBB)7 which divides the cerebral circulation from brain tissue. These cells are interconnected by tight and adherens junction proteins8 whose integrity is critical for stroke outcome.9 Indeed, disruption of the BBB following ischaemia/reperfusion (I/R) leads to vascular leakage and infiltration of plasma components into the brain tissue leading to oedema and further organ damage.9–11 Overproduction of reactive oxygen species (ROS) following I/R is considered a key mechanism leading to BBB damage.12 p66Shc, an isoform of the mammalian adaptor protein Shc,13,14 is a crucial mediator of ROS production in several disease states15–18 thereby leading to cellular apoptosis.19–21 Indeed, much of the vasculoprotective properties observed by genetic deletion of p66Shc in mice are the result of reduced oxidative stress and in turn preserved endothelial function.15–17

In line with the above, we previously demonstrated that mice lacking p66Shc develop smaller stroke size following I/R.22 However, the clinical relevance of this observation remains unknown and the underlying molecular mechanisms poorly understood. To this end, we subjected mice to I/R brain injury, as described.22 In line with the above, we previously demonstrated that mice lacking p66Shc develop smaller stroke size following I/R.22 However, the clinical relevance of this observation remains unknown and the underlying molecular mechanisms poorly understood. To this end, we subjected mice to I/R brain injury, as described.22 In line with the above, we previously demonstrated that mice lacking p66Shc develop smaller stroke size following I/R.22 However, the clinical relevance of this observation remains unknown and the underlying molecular mechanisms poorly understood. To this end, we subjected mice to I/R brain injury, as described.22

Methods

Patients

Twenty-seven patients admitted to the emergency room of San Raffaele Hospital (OSR, Milan, Italy) with a diagnosis of acute ischaemic stroke presenting within 6 h from symptom onset were enrolled. Five patients presented wake-up stroke and were recruited within 6 h from awakening. The initial diagnosis was based on clinical history, neurological examination (conducted by certified neurologists), and a brain computed tomography (CT) scan. Nineteen sex- and age-matched healthy volunteers (either relatives or visitors of in-hospital patients), with a negative history of cardio- and cerebrovascular diseases, were included as controls. Patients diagnosed with diabetes, systemic inflammatory diseases, acute infections, and malignancy were excluded, to eliminate potential interference of those disease states on p66Shc expression.23 Blood was withdrawn from the antecubital vein at 6 and 24 h after initial stroke symptoms (for stroke patients), whereas control subjects donated blood once.

Of the 27 ischaemic stroke patients, 14 received thrombolytic treatment within 4.5 h from initial stroke symptoms onset. Ischaemic strokes were clinically classified according to the Oxford Community Stroke Project classification (also known as the Bamford or OXFORD classification).24 Stroke aetiology was classified according to the Trial of Org 10172 in Acute Stroke Treatment criteria.25 Moreover, stroke severity was assessed, using NIHSS on admission and at discharge. Furthermore, delta NIHSS was calculated as the difference between the NIHSS presented at discharge and the NIHSS presented at admission (delta NIHSS = NIHSS discharge – NIHSS admission); thereby, positive values indicate short-term neurologic worsening while negative values indicate neurological improvement.

The study was approved by the local Ethics Committee at San Raffaele Scientific Institute, Milan, Italy. All participants (or their representative relatives) signed a written informed consent to authorize the treatment of their biological and clinical data.

Isolation of peripheral blood monocytes

Peripheral blood monocytes from whole blood were isolated using anti-CD14-coated MicroBeads (Miltenyi Biotec) on a magnetic separator (Miltenyi Biotech), as previously described.26

Animals

All animal experiments were performed on male, 11–13-week-old wild-type (wt) (C57/BL6J) mice. Study design and experimental protocols were approved by the Cantonal Veterinary Office of the Canton of Zurich.

Middle cerebral artery occlusion

A transient middle cerebral artery (MCA) occlusion (MCAO) surgery was performed on wt mice to induce I/R brain injury, as described.27 In brief, anaesthesia was induced with 3% isoflurane in oxygen-enriched air and mice were kept under 1.5% isoflurane anaesthesia during MCAO surgery. Body temperature was controlled by using a warm water heating pad. Incision site was infiltrated with 0.5% bupivacaine solution for pain relief. A 6-0 silicone-coated filament (Doccoll Corporation) was advanced into the internal carotid artery (ICA) until the thread occluded the origin of the left MCA to induce unilateral MCAO. After 45 min (60 min for evaluation of long-term effect) of ischaemia, the thread was removed to allow reperfusion of the MCA. After wound care and before returning to their standard cage, mice were kept for 1.5 h in a temperature controlled cage. For sham operation, the filament was advanced into the ICA without occluding the MCA.
In vivo p66\textsuperscript{Shc} silencing

In vivo p66\textsuperscript{Shc} silencing was performed as described. Briefly, 1.6 nmol of predesigned siRNA targeting p66\textsuperscript{Shc} was incubated with a mixture of 150 mmol/L NaCl solution-jetPEI\textsuperscript{R} and injected intravenously into the tail vein of the wt mouse randomized. Scrambled siRNA was used as a negative control. Detailed methods are provided in Supplementary material online.

Magnetic resonance imaging

Lesion development was monitored after MCAO on a Bruker Pharmascan 47/16 (Bruker BioSpin GmbH) operating at 4.7 T. Anaesthesia was induced using 3% isoflurane (Abbott) in a 4:1 air–oxygen mixture. During MRI acquisition, mice were kept under isoflurane anaesthesia (1.5%). During the scan session, body temperature was monitored with a rectal temperature probe (MLT415, ADInstruments) and kept at 36 ± 0.5°C using a warm water circuit integrated into the animal support (Bruker BioSpin GmbH). Magnetic resonance imaging (MRI) recordings were done in a blinded way by an independent person.

The lesion was determined on maps of the apparent diffusion coefficient (ADC) derived from diffusion-weighted images as areas of significant reduction of the ADC compared with the unaffected, contralateral side. The lesion in the T2-weighted image was determined as hyperintense areas compared with the contralateral hemisphere. Lesion volumes were quantified blinded by drawing regions of interest around the areas of reduced ADC and hyperintensities in T2-weighted images in five MRI slices using an ROI tool (Paravision, Bruker). Brain infarct volumes were calculated by summing the volumes of each section and correcting for brain swelling, as described. Detailed methods are provided in Supplementary material online.

Neurological deficits measurement

Neurological status was assessed using an adapted four-point scale test based on Bederson et al. and was graded as previously described: Grade 0: normal neurological function; Grade 1: forelimb flexion; Grade 2: circling; Grade 3: leaning to the contralateral side at rest; Grade 4: no spontaneous motor activity. Motor performance was assessed using the RotaRod test. Mice were placed on a rotating rod (9 cm) and the latency to fall was measured. The experimental trial with increasing speed (4–44 revolutions/min; circumference of the rod: 47/16 cm) was repeated using a score sheet that was approved by the Veterinary Office of the Canton of Zurich. This score sheet was used to calculate the neurological deficit score up to 6 days. The well-being of mice during the experimental period was determined using the RotaRod test. Mice were placed on a rotating rod (9 cm) and the latency to fall was measured. The experimental trial with increasing speed (4–44 revolutions/min; circumference of the rod: 47/16 cm) was repeated using a score sheet that was approved by the Veterinary Office of the Canton of Zurich. This score sheet was used to calculate the neurological deficit score up to 6 days. The well-being of mice during the experimental period was determined using the RotaRod test.

Evans blue extravasation

Evans blue extravasation determination of BBB permeability after MCAO was done by evaluating Evans blue extravasation, as described. Detailed methods are provided in Supplementary material online.

Immunofluorescence staining

Frozen brains were cut into 6 μm thick slices on a cryostat (Leica Cm 1900). Immunofluorescent analysis was performed as described.

Briefly, brain slices were fixed in 4% paraformaldehyde and incubated with primary and secondary antibodies. Images were taken using a Leica Dm4000 B microscope. Stained area of claudin-5, vascular endothelial (VE)-cadherin, or occludin was measured using ImageJ Software and normalized to the total endothelial cell surface (assessed by isoelectric B4 staining). Detailed methods are provided in Supplementary material online.

RNA isolation and reverse transcription

Total RNA isolation and preparation of cDNA was performed as previously described. Total RNA of PBM, or of MCA, was extracted using Trizol Reagent (Invitrogen). Two micrograms (MCA) or 1 μg (PBM) of RNA was reverse transcribed using Ready-To-Go You-Prime First-Strand Beads (Amersham Biosciences) and first-strand random cDNA primers pd(N)6 (Takara).

Real-time polymerase chain reaction

Determination of p66\textsuperscript{Shc} gene expression was done as previously described. Detailed methods are provided in Supplementary material online.

Cell culture experiments

Primary HBMECs (Cell Systems) were cultured in EBM-2 medium supplied with EGM-2 bullet kit (Lonza). Adhering cells (passages 5–9) were grown to confluence and exposed to hypoxia (0.2% oxygen) for 4 h, followed or not by 4 h of incubation in a normoxic incubator (reoxygenation). Hypoxia was induced using a gas-controlled glove box (InvivO2 400, Ruskinn Technologies). In certain experiments, cells were pre-incubated with apocynin (0.1 mmol/L) (SAFC) for 1 h. Thereafter, HBMECs were harvested for measuring superoxide anion (O\textsuperscript{2−}) production, nitric oxide (NO) bioavailability, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity or immunoblot analysis.

Small interfering RNA transfection in human brain microvascular endothelial cells

Human brain microvascular endothelial cells were incubated with predesigned siRNA targeting p66\textsuperscript{Shc} at final concentration of 25 nmol/L using lipofectamine\textsuperscript{R} RNAiMAX Reagent (Invitrogen), as previously described.

Detailed methods are provided in Supplementary material online.

Immunoblotting

Basilar arteries and cells were lysed in lysis buffer and proteins were separated using SDS–PAGE, as previously described. Detailed methods are provided in Supplementary material online.

Measurement of O\textsuperscript{2−} production and nitric oxide bioavailability

Electron spin resonance spectroscopy was applied to determine O\textsuperscript{2−} production and NO bioavailability, as described. Detailed methods are provided in Supplementary material online.

Nicotinamide adenine dinucleotide phosphate oxidase activity

Nicotinamide adenine dinucleotide phosphate oxidase activity was determined indirectly by measuring the ratio of NADP/NADPH using a commercially available kit (Abcam), according to the manufacturer’s recommendations.
Figure 1  In vivo silencing of p66Shc. (A) Real-time polymerase chain reaction reveals reduced p66Shc levels in middle cerebral artery homogenates 24 h (n = 5–6) and 48 h (n = 7–8) after p66Shc small interfering RNA injection compared with scrambled small interfering RNA injection (siScr). Data are expressed as mean ± s.e.m. *P < 0.05 for sip66Shc vs. siScr. (B) Immunoblot analysis confirms silencing of p66Shc in basilar arteries within 48 h after p66Shc small interfering RNA injection (representative immunoblot of at least five animals per group). (C–N) Flow cytometry analysis of brain single cell suspensions 24 h after injection of Alexa546-sip66Shc (upper panel) when compared with negative control (lower panel). Singlets (Cand I) with nuclei (D and J) were plotted in a dot plot of APC (CD45) vs. AlexaFluor488 (CD31) to distinguish endothelial cells (CD45−CD31+), leukocytes (CD45+CD31−), as well as other cell types (CD45−CD31−) (E and K). Histograms show Alexa546-fluorescence representing content of Alexa546-sip66Shc in endothelial cells (F and L), leukocytes (G and M), and other cell types (H and N).
Statistical analysis

Statistical analysis for comparison of two groups was performed using two-tailed unpaired Student’s t-test, or Mann–Whitney test, when appropriate. For comparison of more than two unmatched groups, one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test, or Kruskal–Wallis test followed by Dunn’s post hoc test, when appropriate, was performed. For comparison of groups with repeated measures, two-way ANOVA followed by Bonferroni post hoc test was applied. Statistical analysis for survival studies was performed using log-rank (Mantel-Cox) test. Pearson’s correlation analysis was used to test the correlation between two quantitative variables, and Fisher’s exact test for comparison of categorical data between study subjects. Two-sided P-values were calculated and P < 0.05 denoted a significant difference. Statistical analysis was performed using GraphPad Prism software 5.01.

Results

In vivo post-ischaemic silencing of p66Shc reduces lesion volumes and improves functional outcome following I/R brain injury

To study the effect of post-ischaemic p66Shc silencing on stroke, a transient MCAO surgery was performed on wt mice to induce I/R brain injury. To analyse p66Shc silencing efficiency in vivo beforehand, p66Shc mRNA and protein levels were quantified in cerebral arteries (MCA and basilar artery, respectively). Intravenous injection of siRNA against p66Shc reduced mRNA and protein p66Shc levels within 48 h after injection compared with siScr injection (Figure 1A and B). To localize the distribution of the p66Shc siRNA within brain cerebral arteries, wt mice were injected with fluorescence dye-labelled p66Shc siRNA (Alexa546-sip66Shc). Flow cytometry with whole brain digests revealed a predominant uptake of the siRNA by the brain endothelium. We observed that 21.2% of brain endothelial cells (CD45–CD31+) showed a positive signal for Alexa546-tagged p66Shc siRNA (Figure 1F) while only 0.6% of leukocytes (CD45+CD31–) (Figure 1G) and 0.2% of other nucleated cells (CD45–CD31+) (Figure 1H) were positive for the Alexa546 signal. Negative control was stained with Hoechst 33342 to label nucleated cells (Figure 1L–N).

Lesion volumes in sip66Shc and siScr injected stroke mice were quantified with MRI. Diffusion-weighted imaging (DWI) denoted matching baseline lesion sizes in both groups after 45 min of ischaemia and directly upon reperfusion (Figure 2B). At 48 h post-MCAO, both DWI and T2-weighted imaging displayed instead a reduced stroke volume in sip66Shc stroke mice when compared with siScr stroke mice (Figure 2B and C).

Neurological deficits after MCAO were assessed using two different tests. Pre-MCAO, both sip66Shc and siScr stroke mice showed normal neurological function throughout the experimental period (n = 5–6).

Figure 2 Impact of post-ischaemic in vivo p66Shc silencing on stroke outcome. (A) Schematic of experimental study design. Upon reperfusion, specific small interfering RNA against p66Shc is injected intravenously in wt mice, and development of lesion and functional deficits were characterized. (B and C) Both, DWI and T2-weighted imaging denote reduced lesions in sip66Shc stroke mice (DWI: n = 5; T2: n = 6) compared with siScr stroke mice (n = 7) at 48 h post-MCAO. (D and E) Evaluation of neurological deficits by using the RotaRod test and a four-point scale test based on Bederson et al.28 Both neurological tests demonstrate less neurological deficits in the sip66Shc stroke group (n = 9) compared with the siScr stroke group (RotaRod: n = 7; Bederson: n = 8). All sham operated animals show normal neurological function throughout the experimental period (n = 5–6). (F) Post-ischaemic silencing of p66Shc increases survival of mice after stroke (n = 15–16). Data are expressed as mean ± s.e.m. *P < 0.05, **P < 0.01 for sip66Shc stroke vs. siScr stroke.
comparable performance in the RotaRod test and on the four-point scale test based on Bederson et al. 29 (Figure 2D and E). At 24 h post-MCAO, we observed in both groups a reduced latency to fall in the RotaRod test. However, at 48 h post-MCAO, sip66Shc stroke mice showed a significant higher persistence on the rotating drum compared with siScr stroke mice (Figure 2D). In line with that, neurological deficits assessed with the scale test were significantly lower in sip66Shc stroke mice compared with siScr stroke mice at 48 h post-MCAO (Figure 2E). All sham operated animas displayed normal neurological functions throughout the experimental period (Figure 2D and data not shown).

By analysing the impact of p66Shc silencing on stroke up to 6 days, we found an improved survival of sip66Shc stroke mice when compared with siScr stroke mice (Figure 2F, 31.25% survival for siScr stroke mice vs. 66.66% for sip66Shc stroke mice). Survival was assessed in accordance to the health evaluation criteria approved by the Cantonal Veterinary Office of the Canton of Zurich; all sham operated animals survived and fulfilled the health evaluation criteria (data not shown).

In vivo p66Shc silencing preserves blood–brain barrier integrity after I/R brain injury

The BBB plays a critical role for the outcome of stroke, 8 and its permeability can be assessed in vivo by quantifying Evans blue extravasation. 9,30 We tested whether post-ischaemic p66Shc silencing preserves BBB permeability after I/R brain injury in mice. Indeed, 48 h post-MCAO p66Shc silencing reduced Evans blue extravasation when compared with mice receiving siScr (Figure 3A).

Blood–brain barrier permeability is regulated by tight and adherens junctional proteins connecting cerebral microvascular endothelial cells. 35 Thus, we analysed the integrity of tight and adherens junctions following I/R brain injury focusing on claudin-5, occludin, and VE-cadherin. Immunofluorescence staining of claudin-5 on coronal brain sections of siScr-treated stroke mice revealed decreased claudin-5-positive stained areas normalized to the total endothelial surface (measured by isolectin B4 staining 31,36) in the ipsilateral hemisphere compared with the contralateral hemisphere (Figure 3B), while this disruption of claudin-5 integrity was not observed in stroke mice receiving sip66Shc (Figure 3B). Unlike claudin-5, occludin and VE-cadherin-positive stained areas were not changed following I/R brain injury in both experimental groups (data not shown).

Role of p66Shc in H/R in primary human brain microvascular endothelial cells

In order to characterize the molecular regulation of claudin-5 by p66Shc and to translate our in vivo murine data to human cells, we exposed HBMECs to hypoxia (H) alone, or hypoxia followed by reoxygenation (H/R). Exposure of HBMECs to hypoxia neither altered phosphorylation of p66Shc at Ser36, a critical step for its pro-apoptotic 37 and pro-oxidant activity, 21 nor total p66Shc protein expression (Figure 4). We assessed claudin-5, occludin and VE-cadherin expression by Western blot analysis. Post- ischemic silencing of p66Shc with si66Shc prevented the downregulation of claudin-5 and occludin expression by H/R (Figure 4A). VE-cadherin expression was not changed by H/R treatment in any experimental group (Figure 4B). Next, we assessed the phosphorylation of p66Shc by Western blot analysis. Post-ischemic silencing of p66Shc with si66Shc prevented the increase in p66Shc phosphorylation by H/R treatment (Figure 4C). These results suggest that p66Shc silencing preserves BBB integrity after I/R brain injury by maintaining the expression of tight and adherens junctional proteins.

Figure 3 p66Shc mediates blood–brain barrier disruption after I/R brain injury. (A) Assessment of blood–brain barrier impairment. p66Shc silenced mice (n = 6) show less Evans blue extravasation compared with siScr stroke mice (n = 5) at 48 h of reperfusion. (B) Representative fluorescence microscopy images of claudin-5 and isolectin B4 (endothelial marker) stained brain sections. Following I/R brain injury, claudin-5-positive stained area normalized to the total endothelial surface is reduced in the ipsilateral hemisphere compared with the contralateral hemisphere in siScr stroke mice (n = 5), but not in sip66Shc stroke mice (n = 5). Scale bar, 35 μm. Data are presented as mean ± s.e.m. *P < 0.05 for siScr stroke ipsilateral vs. siScr stroke contralateral; **P < 0.01 for sip66Shc stroke vs. siScr stroke.
levels significantly, compared with normoxia (Figure 4A). In contrast, exposure to H/R increased phosphorylation of p66Shc at Ser36 compared with normoxia (n = 6). Hypoxia-inducible factor-1α stabilization was used as an indicator for effective hypoxic condition. Hypoxia followed by reoxygenation increases phosphorylation of p66Shc at Ser36 compared with normoxia (n = 6). (C) Representative immunoblot of p66Shc silencing in vitro. Pre-incubation of human brain microvascular endothelial cells with p66Shc small interfering RNA selectively reduces p66Shc levels, without affecting the levels of the two other Shc isoforms p52Shc and p46Shc. (D) H/R leads to an increased \( \text{O}_2^- \) production (n = 12–13) that is blunted after silencing of p66Shc (n = 7–13). Human brain microvascular endothelial cells exposed to H/R show a reduced nitric oxide bioavailability (n = 12) that is elevated after p66Shc silencing (n = 6–12). Human brain microvascular endothelial cells with p66Shc small interfering RNA reduces H/R-increased nicotinamide adenine dinucleotide phosphate oxidase activity (n = 11). Data are expressed as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 for H/R vs. normoxia; #P < 0.05, ##P < 0.01 for H/R with sip66Shc vs. H/R.

**Figure 4** p66Shc mediates H/R-induced damage of human brain microvascular endothelial cells. (A) p66Shc activation remains unchanged after exposure of human brain microvascular endothelial cells to hypoxia compared with normoxia (n = 8). Hypoxia-inducible factor-1α stabilization is used as an indicator for effective hypoxic condition. (B) Hypoxia followed by reoxygenation increases phosphorylation of p66Shc at Ser36 compared with normoxia (n = 6). (C) Representative immunoblot of p66Shc silencing in vitro. Pre-incubation of human brain microvascular endothelial cells with p66Shc small interfering RNA selectively reduces p66Shc levels, without affecting the levels of the two other Shc isoforms p52Shc and p46Shc. (D) H/R leads to an increased \( \text{O}_2^- \) production (n = 12–13) that is blunted after silencing of p66Shc (n = 7–13). Human brain microvascular endothelial cells exposed to H/R show a reduced nitric oxide bioavailability (n = 12) that is elevated after p66Shc silencing (n = 6–12). (F and G) H/R does not alter phosphorylation of endothelial NO synthase at both sites studied (Ser1177 and Thr495) and endothelial NO synthase protein expression compared with normoxia (n = 7). (H) Pre-incubation of human brain microvascular endothelial cells with p66Shc small interfering RNA reduces H/R-increased nicotinamide adenine dinucleotide phosphate oxidase activity (n = 11). Data are expressed as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 for H/R vs. normoxia; #P < 0.05, ##P < 0.01 for H/R with sip66Shc vs. H/R.

**Effect of p66Shc and reactive oxygen species on claudin-5 in vitro**

Human brain microvascular endothelial cells exposed to H/R exhibited reduced protein levels of claudin-5 compared with normoxia (Figure 5A). In contrast, occludin and VE-cadherin protein levels were not affected by exposure to H/R (Figure 5B and C). After both, pre-incubation of HBMECs with p66Shc siRNA and with the antioxidant apocynin claudin-5 levels were elevated under H/R condition (Figure 5D and E).
p66Shc gene expression is increased in patients with ischaemic stroke and correlates to neurological outcome

To provide evidence for a role of p66Shc in human ischaemic stroke, we analysed p66Shc expression in PBMs of patients with ischaemic stroke. A total of 27 ischaemic stroke patients and 19 age- and sex-matched, healthy control subjects were recruited. Clinical characteristics of both groups did not differ statistically (Table 1). p66Shc mRNA levels were significantly increased 6 h after initial stroke symptoms (Figure 6A) and returned to control levels 24 h thereafter (Figure 6A). Of note, p66Shc gene expression at 6 h was comparable in patients with ischaemic stroke regardless of whether they had received thrombolytic treatment or not (Figure 6B). p66Shc transcript levels of all study subjects positively correlated with neurological deficits at admission, measured according to the NIHSS (Figure 6C). Importantly, while p66Shc gene expression of stroke patients which did not receive thrombolytic intervention did not correlate with short-term neurological outcome (NIHSS discharge − NIHSS admission) (Figure 6D), it positively correlated in stroke patients treated with thrombolysis (Figure 6E).

Discussion

In this study, we demonstrate for the first time that post-ischaemic p66Shc silencing reduces brain injury by preserving BBB integrity by preventing claudin-5 level downregulation. The in vivo findings in the mouse were translated to HBMECs exposed to H/R where p66Shc was phosphorylated at Ser36 leading to the reduction in claudin-5 levels via activation of the NADPH oxidase and increased ROS production. Further, we show that p66Shc expression is increased in PBMs of patients with ischaemic stroke within 6 h from onset of symptoms and that p66Shc gene expression correlates to short-term neurological outcome.

In mice, we recently showed that constitutive genetic deletion of p66Shc reduces early stroke size and neurological deficits following I/R brain injury. However, the mechanisms of this effect and its clinical relevance remained elusive. Furthermore, the use of constitutive
that silencing of the pro-oxidant p66Shc after the ischaemic episode interferes with the recovery processes. Indeed, we demonstrate here that reperfusion of an occluded vessel allows reoxygenation of the ischaemic area which promotes recovery of penumbral areas. Nevertheless paradoxically, re-introduction of oxygen in a previous setting. In contrast, RNA interference (RNAi)-based strategies allow delineation of therapeutic time windows as required in the clinical trials. Indeed, several RNAi-based strategies are under investigation in clinical trials. Here, we used a clinically relevant experimental setup with siRNA delivery upon reperfusion to reduce p66Shc levels. Knockout animals only serves as a proof-of-principle and does not allow delineation of therapeutic time windows as required in the clinical setting. In contrast, RNA interference (RNAi)-based strategies allow to modify the expression of a certain target at the post-transcriptional level, thus making it therapeutically interesting. Indeed, several RNAi-based strategies are under investigation in clinical trials. Here, we used a clinically relevant experimental setup with siRNA delivery upon reperfusion to reduce p66Shc levels. Reperfusion of an occluded vessel allows reoxygenation of the ischaemic area which promotes recovery of penumbral areas. Nevertheless paradoxically, re-introduction of oxygen in a previous ischaemic area also causes a surge in free radical generation which interferes with the recovery processes. Indeed, we demonstrate here that silencing of the pro-oxidant p66Shc after the ischaemic episode and upon reperfusion, as it would be the case in stroke patients presenting at the emergency room undergoing thrombolytic treatment, reduces lesion volume, improves neurological function, and increases survival. These data highlight the potential of p66Shc as a novel therapeutic target in stroke patients undergoing thrombolysis.

**Given the key role of BBB permeability in determining stroke outcome**, we characterized its integrity by analysing Evans blue extravasation, a known indicator for vascular leakage. Indeed, and in line with the improved stroke outcome in the sip66Shc stroke mice, BBB disruption was blunted after p66Shc silencing compared with control mice. Cerebral microvascular endothelial cells connected via tight and adherens junctional proteins make up the BBB. A disruption of this tightly regulated structure is known to occur in I/R brain injury and is responsible for vascular leakage and in turn oedema formation. To investigate the molecular mechanisms by which p66Shc preserves BBB integrity after I/R brain injury, we focused in vivo as well as in vitro on claudin-5, occludin and VE-cadherin, three major junctional proteins. Consistently, we...

### Table 1 Characteristics of clinical study population

<table>
<thead>
<tr>
<th>Study population</th>
<th>Controls n = 19</th>
<th>Stroke patients n = 27</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) mean (range)</td>
<td>71.8 (63-83)</td>
<td>73.9 (52-90)</td>
<td>0.42</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>10 (52.6%)</td>
<td>15 (55.6%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td>1 (5.3%)</td>
<td>6 (22.2%)</td>
<td>0.22</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>10 (52.6%)</td>
<td>15 (55.6%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Dyslipidaemia, n (%)</td>
<td>2 (10.5%)</td>
<td>4 (14.8%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Atrial fibrillation, n (%)</td>
<td>0</td>
<td>4 (14.8%)</td>
<td>0.13</td>
</tr>
<tr>
<td>Coronary artery disease, n (%)</td>
<td>0</td>
<td>5 (18.5%)</td>
<td>0.07</td>
</tr>
<tr>
<td>Previous stroke/TIA, n (%)</td>
<td>0</td>
<td>4 (14.8%)</td>
<td>0.13</td>
</tr>
<tr>
<td>Peripheral artery disease, n (%)</td>
<td>0</td>
<td>4 (14.8%)</td>
<td>0.13</td>
</tr>
</tbody>
</table>

**Stroke sub-groups**

<table>
<thead>
<tr>
<th>Stroke sub-groups</th>
<th>tPA n = 14 (51.9%)</th>
<th>w/o tPA n = 13 (48.1%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) mean (range)</td>
<td>69.4 (52–80)</td>
<td>78.6 (64–90)</td>
<td>0.03</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>15 (55.6%)</td>
<td>9</td>
<td>0.25</td>
</tr>
</tbody>
</table>

**OXFORD classification**

<table>
<thead>
<tr>
<th>OXFORD classification</th>
<th>TACI, n (%)</th>
<th>PACI, n (%)</th>
<th>LACI, n (%)</th>
<th>POCl, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large vessels atherosclerosis, n (%)</td>
<td>12 (44.4%)</td>
<td>10 (37.0%)</td>
<td>5 (18.5%)</td>
<td>0</td>
</tr>
<tr>
<td>Card ioebolism, n (%)</td>
<td>13 (48.1%)</td>
<td>6</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Small vessels disease, n (%)</td>
<td>5 (18.5%)</td>
<td>1</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Undetermined cause, n (%)</td>
<td>3 (11.1%)</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

**Stroke severity assessment**

<table>
<thead>
<tr>
<th>Stroke severity assessment</th>
<th>Admission NIHSS, mean (SD)</th>
<th>Discharge NIHSS, mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TACI, n (%)</td>
<td>13.3 (6.7)</td>
<td>12.1 (5.0)</td>
</tr>
<tr>
<td>PACI, n (%)</td>
<td>10.1 (9.9)</td>
<td>5.8 (5.3)</td>
</tr>
</tbody>
</table>

**Early complications**

<table>
<thead>
<tr>
<th>Early complications</th>
<th>Haemorrhagic transformation, n (%)</th>
<th>Cerebral oedema, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TACI, n (%)</td>
<td>4 (17.4%)</td>
<td>6 (26.1%)</td>
</tr>
</tbody>
</table>

Clinical characteristics of controls and stroke patients do not differ statistically. Sub-group analysis shows statistically significant differences in age and NIHSS at discharge between patients treated with thrombolysis and patients which did not receive thrombolysis. Age is given as mean (with ranges) and NIHSS is expressed as mean ± SD.

TIA, transient ischaemic attack; tPA, tissue plasminogen activator; TACI, total anterior circulation infarct; PACI, partial anterior circulation infarct; LACI, lacunar infarct; POCl, posterior circulation infarct; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; NIHSS, National Institutes of Health Stroke Scale.

*aHaemorrhagic transformation and cerebral oedema were determined in stroke patients (n = 23; tPA n = 13, w/otPA n = 10) on CT scan at 24 h after initial stroke symptoms.*
found less reduction in claudin-5 levels after silencing of p66Shc. In contrast, occludin and VE-cadherin levels remained unaltered in both experimental settings. Our data obtained on murine as well as primary human cells indicate that p66Shc mediates BBB disruption by acting specifically on claudin-5 rather than occludin and VE-cadherin.

To characterize the molecular regulation of claudin-5 by p66Shc, we exposed primary HBMECs to H/R, to mimic in vivo settings. Exposure of HBMECs to H/R, but not to hypoxia, increased phosphorylation of p66Shc at Ser36 confirming previous data in renal tubular epithelial cells. Together with our in vivo data, these results suggest that p66Shc is mainly involved in mediating its deleterious effects during reperfusion, rather than during ischaemia. Endothelial ROS production and NO bioavailability are both critical for I/R-induced alteration in BBB permeability and stroke outcome and ROS are known to influence claudin-5 levels in brain endothelial cells. Here, we demonstrate in vitro evidence that endothelial p66Shc silencing in H/R preserves NO bioavailability, reduces NADPH oxidase activation, and decreases ROS generation thus blunting the reduction in claudin-5 levels. This pathway may be also relevant in vivo.

To study p66Shc gene regulation in stroke patients, we performed proof-of-principle experiments assessing its expression in PBMs of acute ischaemic stroke patients. Although it would be of particular interest and relevance to elucidate the role of cerebrovascular p66Shc in stroke patients, sample collection in humans would prove extremely difficult thus, we selected PBMs since those are easily obtainable from whole blood and could still give us interesting insights into gene expression changes. Here we found that p66Shc mRNA levels were increased 6 h after initial stroke symptoms and then returned to basal levels at 24 h. Moreover, p66Shc expression at 6 h correlated to short-term neurological outcome (delta NIHSS) in stroke patients. Interestingly, delta NIHSS correlated to p66Shc expression only in patients undergoing thrombolysis, but not in those without. Although thrombolysis is known to improve neurological outcome after stroke, it is also associated with early reperfusion-induced BBB damage which is known to be mediated by ROS and affects stroke outcome. An increased vascular leakage also favours the accumulation of blood circulating cells in brain tissue thus causing tissue damage via production of free radicals.

This could explain why the correlation between neurological outcome and p66Shc expression is found only in thrombolytic patients where monocytic p66Shc-induced ROS production and the consequent damage is more pronounced. In contrast, in patients not undergoing thrombolysis, the role of reperfusion-induced ROS-dependent injury is less prominent and thus neurological damage is less likely to be dependent on p66Shc-mediated ROS.

Figure 6 p66Shc gene expression in PBMs of ischaemic stroke patients. (A) Real-time polymerase chain reaction determined increased p66Shc mRNA levels in stroke patients 6 h (n = 27), but not 24 h (n = 16) after initial stroke symptoms compared with the levels of control subjects (n = 19). Data are expressed as mean ± s.e.m. (B) p66Shc gene expression 6 h after initial stroke symptoms was determined in sub-groups of stroke patients according as they did (t-PA), or did not (w/o t-PA) receive thrombolytic treatment. Values from controls are also shown for comparisons. p66Shc mRNA levels are not different between both stroke sub-groups (w/o t-PA: n = 13; t-PA: n = 14). Both sub-groups show higher p66Shc levels compared with controls. Data are expressed as mean ± s.e.m. (C) Correlation between p66Shc gene expression and NIHSS at admission of all study subjects (n = 46). (D and E) Correlation analysis of p66Shc transcripts and delta NIHSS (NIHSS discharge − NIHSS admission) in w/o t-PA patients (n = 13) and in t-PA patients (n = 14). For (C–E) linear regression trend lines are illustrated. ***P < 0.001. NIHSS, National Institutes of Health Stroke Scale; t-PA, tissue plasminogen activator.
In summary, the present study sets the stage for follow-up clinical studies aimed at assessing the potential for p66Shc to become a novel therapeutic target as an adjunct of thrombolysis for the management of acute ischaemic stroke.

Supplementary material
Supplementary Material is available at European Heart Journal online.

Acknowledgements
We thank Prof. Gianvito Martino from the Neuroimmunology Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy, for his intellectual and technical contribution.

Funding
This work was supported by the Swiss National Science Foundation (grant number 310030_147017 to G.G.C., 310030-135815 to T.F.L., and 136822 to J.K.) and Helmut-Horton Foundation to G.G.C.

Conflict of interest: none declared.

References


